All News
Oral IL-23 Inhibitor Effective in Psoriasis
The NEJM has published the results of the FRONTIER 1 trial demonstrating the efficacy of JNJ-77242113, an oral interleukin-23 (IL-23) receptor antagonist peptide, in patients with psoriasis (PSO).
Read Article
Racial and Ethnic Determinants of Psoriatic Arthritis
A study from a large metropolitan registry of psoriatic arthritis (PsA) patients showed several racial and/or ethnic groups are underrepresented and demonstrate differences in disease activity.
Read Article
Pre-Treatment Testing with Biologics Falls Short
US commercial insurance claim analysis of laboratory screening and monitoring practices in chronic inflammatory skin disease (CISD) patients shows that < 60% received the recommended pretreatment testing when starting systemic immunomodulatory treatment.
Read Article
Danish registries study shows maternal Autoimmune Dzs (all) were assoc w/ incr risk of childhood cancers (OR=1.25, 95% CI 1.06, 1.47), acute lymphoblastic leukemia (OR =1.52), Burkitt lymphoma (OR=2.6) & CNS tumors (OR=1.45); same seen for RA mothers https://t.co/HQO972ch9R https://t.co/dDEJUo8unq
Dr. John Cush RheumNow ( View Tweet)
Racial and Ethnic Determinants of Psoriatic Arthritis
A study from a large metropolitan registry of psoriatic arthritis (PsA) patients showed several racial and/or ethnic groups are underrepresented and demonstrate differences in disease activity.
https://t.co/lHQxchTSyU https://t.co/AcXcpvuGI8
Dr. John Cush RheumNow ( View Tweet)
Enthesitis @lihi_eder
@RheumNow #RNL2024
- NSAID - 1st line in mild/isolated
- GC injxn but caution at Achilles
- MTX cond rec by GRAPPA (SEAM PsA)
- All bDMARD work vs PBO (TNFi, IL17, 12/23, 23, JAK, PDE4) - none superior
- IL17 v ADA: higher resol for IXE v ADA, but mixed data https://t.co/20KnQo4kpq
Links:
Eric Dein ericdeinmd ( View Tweet)
Advanced therapies in enthesitis. Don't believe the spin, they all work, no clear evidence that any agent is better than others. @lihi_eder @RheumNow #RNL2024 https://t.co/FwLMUmmClB
Richard Conway RichardPAConway ( View Tweet)
#RNL2024 @RheumNow
@lihi_eder on enthesitis
- ~1/3 PsA, SpA
- Enthesitis precedes onset of PsA in PsO, high u/s score ass. w/ RFs (BMI, nail dyst)
- Exam: tenderness (non-specific), as swelling uncommon. U/s helpful, but non-specif
- Marker of severity, higher risk of damage
Eric Dein ericdeinmd ( View Tweet)
Enthesitis precedes the onset of PsA in PsO patients. Dr. @lihi_eder discusses the importance of US in evaluation of these patients.
#RNL2024 @RheumNow https://t.co/bPLR7zpNe2
Dr. Rachel Tate uptoTate ( View Tweet)
@reumacia @RheumNow You are absolutely right. The point was not generally used for psoriasis ( not PsA). I was surprised my self 🤕.
Here is the slide again by Dr. Armstrong , great talk by the way. Let me know if you want the handout. https://t.co/C11Gkn2jho
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Unique and selective allosteric mechanism of deucravacitinib.
Eric Ruderman
#RNL2024
@RheumNow https://t.co/Zm3bYGR9JJ
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Diagnostic delay in SpA
2.3 years longer delay in diagnosis in women with PsA.
@lihi_eder
#RNL2024
@RheumNow https://t.co/d9ao8vvpa5
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Deucravacitinib takes longer to work for PsO compared to UPA, IL-17i or IL23i; it’s better than apremilast. Side effects w/TYK2i: acne, mild⬆️CK, but zoster & lipid issues aren't seen much, & no CV risk warnings; Dr. Strober doesn't follow labs w/TYK2i. #RNL2024 @rheumnow https://t.co/05jKqL4wdx
TheDaoIndex KDAO2011 ( View Tweet)
Clinical pearl from #RNL2024 @RheumNow
Palmoplantar psoriasis is a great time for first-line JAK inhibitor - Ben Strober, Yale dermatology
JAK for atopic dermatitis - extremely rapid responses https://t.co/hHYdGl51n2
Links:
Eric Dein ericdeinmd ( View Tweet)
"If you are throwing a JAKi at these patients (see below) you are gonna make them better." Dr. Bruce Strober reporting on potential patients/disease states who may respond to JAKi. #RNL2024 @RheumNow https://t.co/bghPuszu5t
Dr. Rachel Tate uptoTate ( View Tweet)
#RNL2024 @RheumNow
Bruce Strober on JAK in skin diseases - diverse benefits:
- PsO
- Atopic dermatitis
- Alopecia areata
- Hidradenitis suppurativa
- Vitiligo
- Lichen planus any many others https://t.co/I9XHVbFpvQ
Eric Dein ericdeinmd ( View Tweet)
So why should you consider JAKi?
Multiple reasons provided by @JointMD including efficacy in domains, it's PO, reasonable safety.
#RNL2024 @RheumNow https://t.co/BgFjhb18Ad
Dr. Rachel Tate uptoTate ( View Tweet)
Random effect in ACR20 responses in male versus females in PsA.
No sex differences in ACR20 responses in patients on JAK/TYK2i .
@lihi_eder
#RNL2024
@RheumNow https://t.co/fgEORm0nKc
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Sex/Gender disparities in rheumatology.
@lihi_eder
#RNL2024
@RheumNow https://t.co/PB7zPYJHd0
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
More evidence to support role of Tyk2 in management
of skin psoriasis.
Dr.April Armstrong
#RNL2024
@RheumNow https://t.co/9vuuhJMj36
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
